TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling

Lung Cancer

Volumn 97, Issue , 2016, Pages 48-50

  Zhu, Viola Weijia ^a   Upadhyay, Daya ^a   Schrock, Alexa B ^b   Gowen, Kyle ^b   Ali, Siraj M ^b   Ou, Sai Hong Ignatius ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FOUNDATION MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Comprehensive genomic profiling; Intra chromosomal deletion; ROS1 rearranged NSCLC; TPD52L1 ROS1

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; HYBRID PROTEIN; TPD52L1 ROS1 FUSION PROTEIN; UNCLASSIFIED DRUG; CRIZOTINIB; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN; TPD52L1 PROTEIN, HUMAN; TUMOR PROTEIN;

ADENOSQUAMOUS CARCINOMA; ADJUVANT THERAPY; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CASE REPORT; CELL CYCLE REGULATION; CHROMOSOME 6Q; CHROMOSOME 6Q22; CHROMOSOME DELETION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIMERIZATION; ENDOBRONCHIAL ULTRASONOGRAPHY; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE REARRANGEMENT; HUMAN; IMAGE GUIDED BIOPSY; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ADENOSQUAMOUS CELL CARCINOMA; LUNG BIOPSY; LUNG NODULE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; MEDIASTINUM LYMPH NODE; PNEUMOTHORAX; PRIORITY JOURNAL; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; THORAX RADIOGRAPHY; ADJUVANT CHEMORADIOTHERAPY; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC IMAGING; EXON; GENETICS; GENOMICS; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SECONDARY;

AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; EXONS; GENOMICS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRAZOLES; PYRIDINES;

EID: 84964499654     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.04.013     Document Type: Article

References (11)

1. Zhu Q., Zhan P., Zhang X., et al. Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. Transl. Lung Cancer Res. 2015, 4:300-309.
2. Kazandjian D., Blumenthal G., Luo L., et al. FDA approval summary: crizotinib for the treatment of patients with ROS1 alteration-positive metastatic NSCLC. Oncologist 2016, (in press).
3. Ou S.H., Chalmers Z.R., Azada M.C., et al. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. Lung Cancer 2015, 88:352-354.
4. Frampton G.M., Fichtenholtz A., Otto G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 2013, 31:1023-1031.
5. Byrne J.A., Nourse C.R., Basset P. Identification of homo- and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system. Oncogene 1998, 16:873-881.
6. Shaw A.T., Ou S.H., Bang Y.J., et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014, 371:1963-1971.
7. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008, 99:2349-2355.
8. Lee J., Kim H.C., Hong J.Y., et al. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget 2015, 6:24320-24332.
9. Sathasivam P., Bailey A.M., Crossley M., et al. The role of the coiled-coil motif in interactions mediated by TPD52. Biochem. Biophys. Res. Commun. 2001, 288:56-61.
10. Boutros R., Byrne J.A. D53 (TPD52L1) is a cell-cycle regulated protein maximally expressed at the G2-M transition in breast cancer cells. Exp. Cell Res. 2005, 310:152-165.
11. Zheng Z., Liebers M., Zhelyazkova B., et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 2014, 20:1479-1484.